S. Moncada and E. A. Higgs, Endogenous nitric oxide: physiology, pathology and clinical relevance, European Journal of Clinical Investigation, vol.8, issue.4, pp.361-74, 1991.
DOI : 10.1097/00000441-189305000-00001

J. A. Bauer and H. L. Fung, Differential hemodynamic effects and tolerance properties of 557 nitroglycerin and an S-nitrosothiol in experimental heart failure, J. Pharmacol. Exp. Ther, vol.256, pp.558-249, 1991.

J. D. Parker and T. Gori, Tolerance to the organic nitrates: new ideas, new mechanisms, 560 continued mystery, Circulation, vol.104, pp.2263-2268, 2001.

U. Förstermann and T. , Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace, Circulation, vol.113, issue.13, pp.1708-1722, 2006.
DOI : 10.1161/CIRCULATIONAHA.105.602532

C. Gaucher, A. Boudier, F. Dahboul, M. Parent, and P. Leroy, S-nitrosation/denitrosation in 564 cardiovascular pathologies: facts and concepts for the rational design of S-nitrosothiols, Curr, p.565

C. Mancuso, A. Bonsignore, E. D. Stasio, A. Mordente, and R. Motterlini, Bilirubin and S- 567 nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric 568 oxide, Biochem. Pharmacol, pp.66-2355, 2003.

J. L. Alencar, I. Lobysheva, K. Chalupsky, M. Geffard, F. Nepveu et al., 570 S-nitrosating nitric oxide donors induce long-lasting inhibition of contraction in isolated 571 arteries, J. Pharmacol. Exp. Ther, pp.307-152, 2003.

B. Furlong, A. H. Henderson, M. J. Lewis, and J. A. Smith, Endothelium-derived relaxing factor 573 inhibits in vitro platelet aggregation, Br. J. Pharmacol, pp.90-687, 1987.
DOI : 10.1111/j.1476-5381.1987.tb11221.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1987.tb11221.x/pdf

H. Al-sa-'doni and A. Ferro, S-nitrosothiols as nitric oxide-donors: chemistry, biology and 575 possible future therapeutic applications, -Minet, 577 C. Gaucher, Polymer nanocomposites enhance S-nitrosoglutathione intestinal absorption and 578 promote the formation of releasable nitric oxide stores in rat aorta, Nanomed. Nanotechnol, pp.2679-90, 2004.

]. F. Dahboul, C. Perrin-sarrado, A. Boudier, I. Lartaud, R. Schneider et al., 581 dinitrosobucillamine, a new nitric oxide donor, induces a better vasorelaxation than other S- 582 nitrosothiols S- 584 nitrosophytochelatins: investigation of the bioactivity of an oligopeptide nitric oxide delivery 585 system Therapeutic potential of S- 587 nitrosothiols as nitric oxide donor drugs In vivo pharmacological activity 589 and biodistribution of S-nitrosophytochelatins after intravenous and intranasal administration 590 in mice Bucillamine: a potent thiol donor with multiple clinical applications Efficacy and safety of bucillamine, a 594 D-penicillamine analogue, in patients with active rheumatoid arthritis, Biol. Med. Eur. J. Pharmacol. Biomacromolecules Scott. Med. J. Nitric Oxide Cardiovasc. Drug Rev. Mod. Rheumatol, vol.1216, issue.16, pp.1795-1803, 1997.

. Maincent, Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?, Eur. 598, J. Pharm. Biopharm, vol.85, issue.599, pp.640-649, 2013.

]. M. Parent, F. Dahboul, R. Schneider, I. Clarot, P. Maincent et al., A 603 complete physicochemical identity card of S-nitrosoglutathione, Structure and Stability 606 Studies of Pharmacologically Relevant S-Nitrosothiols: A Theoretical Approach, pp.602-633, 2013.

E. Chem, B. Cancès, J. Mennucci, and . Tomasi, Accurate and simple analytic representation of the electron-gas 609 correlation energy A new integral equation formalism for the 611 polarizable continuum model: Theoretical background and applications to isotropic and 612 anisotropic dielectrics, Phys Rev B Condens Matter J. Chem. Phys, vol.120, issue.613, pp.4191-200, 1992.

J. V. Foresman, J. Ortiz, D. J. Cioslowski, . Fox, . Gaussian-09 et al., Forced 626 Degradation Studies of Ivabradine and In Silico Toxicology Predictions for Its New 627 Designated Impurities Measurement of Nitric Oxide Production in 629 Biological Systems by Using Griess Reaction Assay Megson, S-nitrosothiols cause prolonged, nitric 631 oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic 632 potential in bypass surgery, Front. Pharmacol. Br. J. Pharmacol, vol.727, issue.630, pp.625-276, 2000.

. Vasodilators, and ventricular end-systolic stress in nonanesthetized 635 unrestrained rats, Hypertension, vol.30, issue.636, pp.1169-74, 1997.

R. Andersen, G. Schulz, U. Heusch, M. Modder, D. Kelm et al., Detection of S-nitrosothiols in 640 biological fluids: a comparison among the most widely applied methodologies Determination 643 of S-nitrosoglutathione in plasma: comparison of two methods Catalysis of thiol/disulfide 645 exchange. Glutaredoxin 1 and protein-disulfide isomerase use different mechanisms to 646 enhance oxidase and reductase activities Characterisation of the decomposition behaviour of 648 S-nitrosoglutathione and a new class of analogues: S-Nitrosophytochelatins, The opposite effects of nitric 651 oxide donor, S-nitrosoglutathione, on myocardial ischemia/reperfusion injury in diabetic and 652 non-diabetic mice, pp.1699-705, 2005.

M. Parent, C. Nouvel, M. Koerber, A. Sapin, P. Maincent et al., PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release, Journal of Controlled Release, vol.172, issue.1, pp.292-304, 2013.
DOI : 10.1016/j.jconrel.2013.08.024

URL : https://hal.archives-ouvertes.fr/hal-01273194